The detection of NRAS Q61K/R mutations has been reported in MM patients who progressed on BRAF/MEKi treatment, and this was found to be positively correlated with an increase in BRAF mutant ctDNA levels. This evidence concerns the gene BRAF and Miyoshi myopathy.